Want to see ANIP full AI Analyst Report?
ANIP Stock Chart & Stats
$75.65
$0.72(0.93%)
At close: 4:00 PM EDT
$75.65
$0.72(0.93%)
Day’s Range― - ―
52-Week Range$70.15 - $99.50
Previous Close$78.37
Volume352.39K
Average Volume (3M)374.76K
Market Cap
$1.68B
Enterprise Value$2.05K
Total Cash (Recent Filing)$360.21M
Total Debt (Recent Filing)$330.34M
Price to Earnings (P/E)14.9
Beta0.47
Next Earnings
Nov 11, 2026EPS Estimate
2.16Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)4.83
Shares Outstanding22,959,488
10 Day Avg. Volume409,106
30 Day Avg. Volume374,757
Financial Highlights & Ratios
PEG Ratio-0.05
Price to Book (P/B)2.93
Price to Sales (P/S)1.79
P/FCF Ratio10.49
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$110.83Price Target Upside46.51% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)9.29
Revenue Forecast (FY)$1.11B
Bulls Say, Bears Say
Bulls Say
Cortrophin GrowthCortrophin is becoming a major growth platform, with expanding demand across multiple specialties and a larger commercial team. Sustained adoption could materially improve ANI’s revenue mix and support continued operating leverage.
Generics PipelineConsistent generic launches and in-house pharmaceutical capabilities provide recurring opportunities to replace mature products and broaden revenue. This pipeline also diversifies growth beyond Cortrophin and supports manufacturing scale.
Balance SheetStrong operating cash generation, substantial liquidity and reduced net leverage improve ANI’s financial flexibility. The healthier capital structure can support product investment, business development and execution through operating volatility.
Bears Say
Cortrophin Timing RiskAlthough Cortrophin remains a strong growth driver, the guidance adjustment shows that demand conversion and timing are not fully predictable. Continued execution or access friction could make results more dependent on one product.
Margin PressureHigher manufacturing costs and investment in the expanded gout sales force are absorbing part of the revenue benefit. If these expenses persist faster than product growth, margin expansion and earnings conversion could remain constrained.
Earnings ConsistencyThe historical losses and weaker recent cash-flow growth indicate that profitability is not yet consistently resilient. Working-capital effects, one-time items or cost swings could reduce the reliability of reported earnings and cash generation.
ANI Pharmaceuticals News
ANIP FAQ
What was ANI Pharmaceuticals Inc’s price range in the past 12 months?
ANI Pharmaceuticals Inc lowest stock price was $70.15 and its highest was $99.50 in the past 12 months.
What is ANI Pharmaceuticals Inc’s market cap?
ANI Pharmaceuticals Inc’s market cap is $1.68B.
When is ANI Pharmaceuticals Inc’s upcoming earnings report date?
ANI Pharmaceuticals Inc’s upcoming earnings report date is Nov 11, 2026 which is in 67 days.
How were ANI Pharmaceuticals Inc’s earnings last quarter?
ANI Pharmaceuticals Inc released its earnings results on Aug 07, 2026. The company reported $2.21 earnings per share for the quarter, beating the consensus estimate of $2.043 by $0.167.
Is ANI Pharmaceuticals Inc overvalued?
According to Wall Street analysts ANI Pharmaceuticals Inc’s price is currently Undervalued.
Does ANI Pharmaceuticals Inc pay dividends?
ANI Pharmaceuticals Inc does not currently pay dividends.
What is ANI Pharmaceuticals Inc’s EPS estimate?
ANI Pharmaceuticals Inc’s EPS estimate is 2.16.
How many shares outstanding does ANI Pharmaceuticals Inc have?
ANI Pharmaceuticals Inc has 22,959,488 shares outstanding.
What happened to ANI Pharmaceuticals Inc’s price movement after its last earnings report?
ANI Pharmaceuticals Inc reported an EPS of $2.21 in its last earnings report, beating expectations of $2.043. Following the earnings report the stock price went down -5.301%.
Which hedge fund is a major shareholder of ANI Pharmaceuticals Inc?
Currently, no hedge funds are holding shares in ANIP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
ANI Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$110.83 (46.51% Upside)
$110.83 (46.51% Upside)
Blogger Sentiment
Neutral
ANIP Sentiment 57%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 691.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $243.5K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 4.8%
Last 30 Days ▼ 4.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-24.15%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
11.25%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
ANI Pharmaceuticals Inc
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally. The company provides injectables, softgel capsules, and Cortrophin gel, as well as ILUVIEN and YUTIQ products. It also manufactures oral solid dose products, semi-solids, liquids, topicals, controlled substances, and potent products. The company serves its products to national wholesalers, specialty pharmacies, retail pharmacy chains, distributors, mail order houses, group purchasing organizations, and hospitals and healthcare providers. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.
ANIP Company Deck
ANIP Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlighted strong operational execution with record Q2 revenue, record adjusted EBITDA, robust Cortrophin momentum, a major sales force expansion, continued generics execution and a healthy balance sheet. Near-term headwinds include timing-related adjustments (modest Cortrophin guidance revision), higher cost of sales and increased SG&A from the gout expansion, and a Q3 EBITDA sequential dip tied to milestone timing and fully loaded expansion costs. Management emphasizes continued confidence in multi-year Cortrophin growth and reaffirmed full-year company guidance, indicating that the positives (growth, margin expansion outlook, cash generation and strategic progress) meaningfully outweigh the short-term operational and timing challenges.View all ANIP earnings summariesANIP Stock 12 Month Forecast
Average Price Target
$110.83
▲(46.51% Upside)
Technical Analysis
―
Pacira Pharmaceuticals
―
Supernus Pharmaceuticals
―
Amphastar Pharmaceuticals
―
Harrow Health
―
Ownership Overview
7.83% Insiders
19.48% Mutual Funds
30.84% Other Institutional Investors
16.22% Public Companies and
Individual Investors